The most common AEs related to durvalumab were pain and cough (16.1%), followed by pneumonitis and AST/ALT abnormalities (12.9%), hypothyroidism, dyslipidemia, fatigue, pruritus, and localized urticaria (6.4%), and anemia, myalgia, pulmonary thrombosis, hypotension, nausea, decreased visual acuity, inappetence, upper airway obstruction, and vomiting (3.2%). Here, GPT is linked to pneumonitis.